Recent Investment Analysts’ Ratings Changes for LivaNova (LIVN)

Several analysts have recently updated their ratings and price targets for LivaNova (NASDAQ: LIVN):

• 3/17/2025 – LivaNova had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $64.00 price target on the stock.
• 3/7/2025 – LivaNova had its price target lowered by analysts at Barclays PLC from $58.00 to $56.00. They now have an “equal weight” rating on the stock.
• 3/3/2025 – LivaNova had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $64.00 to $55.00. They now have a “buy” rating on the stock.
• 2/26/2025 – LivaNova was downgraded by analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating.
• 2/26/2025 – LivaNova had its price target lowered by analysts at Mizuho from $70.00 to $60.00. They now have an “outperform” rating on the stock.
• 2/26/2025 – LivaNova was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 2/26/2025 – LivaNova had its price target lowered by analysts at Stifel Nicolaus from $72.00 to $60.00. They now have a “buy” rating on the stock.
• 2/26/2025 – LivaNova had its price target lowered by analysts at Needham & Company LLC from $75.00 to $64.00. They now have a “buy” rating on the stock.
• 2/14/2025 – LivaNova was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 1/28/2025 – LivaNova had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
• 1/23/2025 – LivaNova was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.

LivaNova Stock Down 2.4 %

LIVN opened at $40.41 on Wednesday. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.48. The stock’s fifty day simple moving average is $45.75 and its 200 day simple moving average is $48.94. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.20 billion, a PE ratio of 96.21 and a beta of 1.10.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its holdings in shares of LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after purchasing an additional 12,470 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of LivaNova during the 4th quarter worth $1,954,000. KBC Group NV grew its holdings in shares of LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after purchasing an additional 56,580 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after purchasing an additional 899 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of LivaNova by 17.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after purchasing an additional 93,311 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.